肿瘤细胞治疗研究
英文原题：Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.
这些数据强调了在CD19 CAR-T细胞治疗后接种COVID-19疫苗的重要性，即使存在长期B细胞发育不全。
接受CD19 CAR T细胞治疗复发/难治性淋巴瘤的患者会出现长期且严重的B细胞再生障碍和低丙种球蛋白血症，使其面临更高的重症COVID-19风险。Oh等人和Atanackovic等人分别证明，尽管对mRNA疫苗的体液反应减弱，患者仍表现出正常或增强的功能性T细胞反应，包括针对SARS-CoV-2变异株（包括Omicron）的抗病毒T细胞活性。总体而言，这些数据强调了在CD19 CAR T细胞治疗后接种COVID-19疫苗的重要性，尽管存在长期B细胞再生障碍。
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.
MEMBER ACCOUNT
登录成功会直接打开下一页。
